GLP-1 drugs are influencing what more than one in five adults across the Americas eat and drink, according to research by Tesco-owned customer data firm Dunnhumby.
After surveying 8,500 consumers across six countries in August, Dunnhumby said each GLP-1 user shapes the dietary habits of an average of 2.08 people within their household – broadening the medication’s reach beyond patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Across the six markets in the Americas surveyed – the US, Canada, Mexico, Brazil, Colombia, and Chile – 10.2% of adults have used a GLP-1 medication, while 21.3% say their food and drink choices are shaped by the drugs.
When asked about household reach, almost one in three US adults – 31.7% – said their consumption habits were influenced by GLP-1 use.
However, the largest multiplier was in Brazil, where 14.4% of respondents used the drugs but 33.3% said the medication had an effect on what they eat and drink.
Usage is highest in the US at 16.7% and Brazil at 14.4%, though Dunnhumby noted 45.6% of all historical users are no longer taking the medication. Drop-off rates were highest in Chile (66.7%) and Mexico (51%), compared with 39% in Canada and 40.2% in the US.
“GLP-1s are not taking demand out of the grocery cart, it’s creating an opportunity” Jamie Samaha, Dunnhumby’s CEO, said. “Spending is moving from bakery, alcohol and prepared meals to fresh produce and healthcare, with only 8% of users who’ve cut back say nothing would win them back.
“The winners will be retailers and brands that can spot these households in their customer data and give them lower-sugar, higher-protein choices.”
Users were most interested in lower-sugar (52.4%), higher-protein (51.6%) and lower-calorie options (42.9%), Dunnhumby said, compared to fewer users (29.7%) who wanted smaller portions or pack sizes.
Among adults considering a GLP-1, cost is the most common reason for not yet using one (26.6%), ahead of prescription access (19.6%) and side effects (18.3%).
Dunnhumby called out Brazil as “the market to watch in Latin America”.
According to the researchers, Brazilian users report the same changes in habits as users in the other markets surveyed “but at around twice the depth”.
Dunnhumby said sales of alcoholic drinks fell 72.9 points among Brazilians using GLP-1 drugs, a rate that was nearly double the overall figure across the six markets.
Ready meals fared the next worst (down 62.1 points) and bakery (53.2 points lower).